2019 American College of Cardiology best conference

Sofía Noria, Sebastián Lorenzo, Carlos Guamán, Yamel Ache, María Victoria Ramos

Article ID: 1663
Vol 2, Issue 1, 2021
DOI: https://doi.org/10.54517/wt.v2i1.1663
VIEWS - 2462 (Abstract)

Download PDF

Abstract

As every year, the 68th American College of Cardiology (ACC) conference was held in New Orleans, Louisiana, from March 16 to 18. With carnival and jazzas the background, he convened the world cardiology again to promote knowledge by displaying a variety of scientific activities. More than 16000 participants attended and 2300 articles were received, many of which will undoubtedly change current clinical practice. It is also worth noting that the introduction of the guidelines for primary pretreatment of cardiovascular diseases emphasizes that acetylsalicylic acid is almost completely abandoned in primary pretreatment due to the lack of net profit.

We will briefly summarize some of the major scientific papers submitted:

1. Antithrombotic therapy after PCI for acute coronary syndrome or atrial fibrillation—Augustus test

2. Transcatheter aortic valve replacement and balloon dilatation in low-risk patients-partner 3 trial

3. Safety and effectiveness of STEMI femoral artery access: Safari STEMI trial

4. One month after drug-eluting stent implantation, clopidogrel monotherapy was compared with clopidogrel standard 12-month dual antiplatelet therapy. Stop dapt 2 test

5. Results of a large-scale application based study using Smartwatch to identify atrial fibrillation: Apple heart research


Keywords

cardiology; meeting; summary


References

1. Lopez RD, Hazer G, Aronson R, et al. Antithrombotic therapy or atrial fibrillation PCI after acute coronary syndrome. Engineering Medicine 2019; 380(16):1509–1524.

2. Ortiz C. 2019 ACC: Apixaban in the treatment of atrial fibrillation and acute coronary syndrome March 20, 2019. Available at: https://www.cardioteca.com/arrit-Mias-blog/atrialfibrillation-atrialfibrillation-atrialfibrillation-anticoagulation/193-atrialfibrillation-api-xaban/3349-Research-augustus-acc-2019-apixa-ban-en-atrialfibrillation-atrialfibrillation-coronarysyndrome-acute. (Accessed: Apr. 13, 2019)

3. Augustus test showed that apixaban had good safety against vitamin K antagonists. Available at: https://www.Farman.COM/notasprensa/13333/Eltestau-gutushasecurityfavresults. (Accessed: Apr. 13, 2019)

4. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines—Guidelines for the management of valvular heart disease. European Heart Journal2017; 38(36):2739–2791.

5. Thyregod HG, steinbruchel DA, ihlemann N, et al. Transcatheter and surgical aortic valve replacement in patients with severe aortic stenosis: Results of a one-year clinical trial. My Heart 2015; 65(20):2184–2194.

6. Thyregod HG, Ihlemann N, Jørgensen TH, et al. The five-year clinical and echocardiographic results of Nordic aortic valve intervention(note) are randomized clinical trials in patients with low surgical risk.Transportation2019.

7. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic valve replacement and balloon dilated valve replacement in low-risk patients. British Journal of Medicine 2019;380(18): 1695–1705.

8. Hughes S. Partner 3: Success of TAVR in low-risk patients. Available at: https://www.Medicallandscape.DocumentCOM/viewarticle/910503. (Accessed: Apr. 12, 2019)

9. Spanish Society of Cardiology. The SEC will take you to ACC19. Available at: https://www.youtube.com/watch?V=SSUTXULKGKY&T=912S. (Accessed: Apr. 15, 2019)

10. Ibanez B, James S, Agewall S, et al. 2017 guidelines for the management of acute myocardial infarction in patients with ESCST segment elevation: European Society of Cardiology (ESC) task force on the management of acute myocardial infarction in patients with ST segment elevation. European Heart Journal 2018; 39(2):119–177.

11. Neumann FJ, Sousa-UvaM, Ahlsson A, et al. 2018 ESC/EACTS guidelines for myocardial revascularization. European Heart Journal 2019; 40(2): 87–165.

12. Le May MR.Femoral and radial access of primary PCI (SAFARI-STEMI). Available at: https://clinicaltrials.Government/CT2/display/nct01398254. (Accessed: Apr. 7, 2019)

13. Babry AA. Safety and effectiveness of femoral and radial access in STEMI: Safari STEMI. Available at: https://www.Acc.org/latestCardiology/clinicaltrials/2019/03/16/23/57/SafariSTEMI. (Accessed: Apr. 7, 2019)

14. Le May M.Safari Stemi: A similar 30-day mortality rate was radial versus femoral PCI. Available at: https://www.Acc.org/latestCardiology/article/2019/03/08/15/32/mon-1045am-safari-stemi-ferma-access-vs-radial-acc-primary-pci-acc-2019. (Accessed: Apr. 7, 2019)

15. Al Aasnag M.Safari, STEMI, stopapt-2, smart choice and more. Available at: https://www.pcronli-No,No.Com/news/whats-new-on-pcronline/2019/acc-2019-day-3-safari-stemi.-Stopapt-2.Smartselection. (Accessed: Apr. 7, 2019)

16. O’Riordan M.Hunting surprise: In STEMI, the radius is larger than the femoral artery, and there is no survival or bleeding advantage. Available at: https://www.tctmd.Com/news/safari-surprise-no-survival-or-blee-ding-advantage-radial-over-femal-access-stemi. (Accessed: Apr. 7, 2019)

17. Tomi T, Morimoto T, Shiomi h, et al. Comparison of clopidogrel monotherapy and standard 12-month clopidogrel dual therapy after drug-eluting stent implantation. Available at: https://www.acc.org/~/media/cli-nical/pdf-files/approved-pdfs/2019/03/15/acc19slides/mar18mon/1145ametstopdapt-2-acc-2019.Pdfformat. (Accessed: Apr. 6, 2019)

18. The short DBH is at least not lower than the standard DBH, and two studies show that. Available at: http://www.crtonline.org/news-detail/short-dapt-Atleastnotlowerthanthestandard. (Accessed: Apr. 8, 2019)

19. Maxwell YL. Aspirin lowering: Two trials explored P2Y12 monotherapy after short-term apt after PCI. Available at: https://www.tctmd.com/news/dropping-Aspirin-twotrials-Exploration-P2Y12-monotherapy-af-ter-shortterm-afterdapt-pci. (Accessed: Apr. 8, 2019)

20. Turakhia MP, Desai M, Hedlin H, et al. The principle and design of a large application based study to identify cardiac arrhythmias using smart watches: Apple heart research. Heart Journal 2019; 207:66–75.

21. Turakhia MP, Pérez M. Results of a large-scale application based study using smart watches to identify cardiac arrhythmias: Apple heart research. Available at: https://www.acc.org/~/media/cli-nical/pdf-files/approved-pdfs/2019/03/15/acc19slides/mar16sat/10ametapple-heart-study-acc-2019.Pdfformat. (Accessed: Apr. 1, 2019)

22. The apple heart study found afib in a small group of Apple watch wearers. Available at: https://www.acc.org/latest-in-car-Dionysus/article/2019/03/08/15/32/sat-9am-Appleheartresearch-acc-2019. (Accessed: Apr. 1, 2019)

23. Apple’s heart research gives people a rough understanding of how wearable technology can help heart rhythm problems. Available at: https://www.acc.org/about-acc/press-releases/2019/October3,2002. (Accessed: Apr. 1, 2019)

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Sofía Noria, Sebastián Lorenzo, Carlos Guamán, Yamel Ache, María Victoria Ramos

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.